Display options
Cite
Bonechi M, Galardi F, Biagioni C, et al. Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy. Oncotarget. 2018;9(23):16389-16399doi: 10.18632/oncotarget.24700.
Bonechi, M., Galardi, F., Biagioni, C., De Luca, F., Bergqvist, M., Neumüller, M., Guarducci, C., Boccalini, G., Gabellini, S., Migliaccio, I., Di Leo, A., Pestrin, M., & Malorni, L. (2018). Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy. Oncotarget, 9(23), 16389-16399. https://doi.org/10.18632/oncotarget.24700
Bonechi, Martina, et al. "Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy." Oncotarget vol. 9,23 (2018): 16389-16399. doi: https://doi.org/10.18632/oncotarget.24700
Bonechi M, Galardi F, Biagioni C, De Luca F, Bergqvist M, Neumüller M, Guarducci C, Boccalini G, Gabellini S, Migliaccio I, Di Leo A, Pestrin M, Malorni L. Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy. Oncotarget. 2018 Mar 27;9(23):16389-16399. doi: 10.18632/oncotarget.24700. eCollection 2018 Mar 27. PMID: 29662653; PMCID: PMC5893248.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2018 Mar 27;9(23):16389-16399. doi: 10.18632/oncotarget.24700. eCollection 2018 Mar 27.

Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy.

Oncotarget

Martina Bonechi, Francesca Galardi, Chiara Biagioni, Francesca De Luca, Mattias Bergqvist, Magnus Neumüller, Cristina Guarducci, Giulia Boccalini, Stefano Gabellini, Ilenia Migliaccio, Angelo Di Leo, Marta Pestrin, Luca Malorni

Affiliations

  1. "Sandro Pitigliani" Translational Research Unit, Hospital of Prato, Prato, Italy.
  2. Bioinformatics Unit, Hospital of Prato, Prato, Italy.
  3. Biovica International, Uppsala Science Park, Uppsala, Sweden.
  4. "Sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Prato, Italy.

PMID: 29662653 PMCID: PMC5893248 DOI: 10.18632/oncotarget.24700

Abstract

The aim of this study was to investigate if thymidine kinase-1 (TK1), a well-known proliferation marker, could represent a valid circulating biomarker to identify hormone receptor positive (HR+)/HER2 negative (HER2neg) metastatic breast cancer (MBC) patients most likely to benefit from endocrine therapy (ET). We used the DiviTum™ assay to analyze TK1 activity in cell lysates of three HR+/HER2neg BC cell lines and in plasma of 31 HR+/HER2neg MBC patients receiving ET. Blood samples were collected at treatment initiation, after one month and at disease progression. CTCs count and

Keywords: circulating biomarkers; endocrine therapy; liquid biopsy; metastatic breast cancer; thymidine kinase-1

Conflict of interest statement

CONFLICTS OF INTEREST Mattias Bergqvist and Magnus Neumüller are employee and shareholders of Biovica International, the company that commercializes the assay used in this work. All the other authors

References

  1. Breast Cancer Res Treat. 2013 Jun;139(3):751-8 - PubMed
  2. N Engl J Med. 2012 Feb 9;366(6):520-9 - PubMed
  3. J Clin Oncol. 2001 Jun 1;19(11):2778-87 - PubMed
  4. Nat Rev Clin Oncol. 2015 Sep;12(9):541-52 - PubMed
  5. Breast Cancer Res. 2017 Nov 21;19(1):123 - PubMed
  6. Cancer Res. 2001 Feb 15;61(4):1421-5 - PubMed
  7. N Engl J Med. 2016 Nov 3;375(18):1738-1748 - PubMed
  8. Oncotarget. 2016 Nov 15;7(46):74448-74459 - PubMed
  9. Br J Cancer. 1990 Oct;62(4):663-7 - PubMed
  10. Lancet Oncol. 2016 Apr;17 (4):425-439 - PubMed
  11. Cancer Res. 1995 Apr 1;55(7):1505-8 - PubMed
  12. Breast Cancer Res Treat. 2012 Jul;134(1):283-9 - PubMed
  13. Expert Opin Med Diagn. 2008 Feb;2(2):129-41 - PubMed
  14. Cancer Biomark. 2010;7(2):65-72 - PubMed
  15. Ann Oncol. 2006 May;17 Suppl 5:v7-12 - PubMed
  16. J Biol Chem. 1973 Apr 25;248(8):2722-9 - PubMed
  17. Curr Oncol Rep. 2017 May;19(5):35 - PubMed
  18. Int J Cancer. 2000 Sep 15;87(6):860-8 - PubMed
  19. N Engl J Med. 2016 Nov 17;375(20):1925-1936 - PubMed
  20. Clin Chem Lab Med. 2013 Feb;51(2):439-47 - PubMed
  21. N Engl J Med. 2015 Jul 16;373(3):209-19 - PubMed
  22. Br J Cancer. 1988 Jun;57(6):619-22 - PubMed
  23. Lancet Oncol. 2015 Jan;16(1):25-35 - PubMed
  24. Anticancer Res. 1999 Jan-Feb;19(1A):437-43 - PubMed
  25. J Clin Lab Anal. 2013 May;27(3):220-6 - PubMed
  26. J Thorac Oncol. 2014 Oct;9(10):1568-72 - PubMed
  27. Cancer Discov. 2011 Sep;1(4):338-51 - PubMed
  28. Breast. 2014 Oct;23(5):489-502 - PubMed
  29. Pharmacol Ther. 1995;67(2):155-86 - PubMed

Publication Types